MétaCan
Menu
← Back to cohort
Record W7117259938 · doi:10.1002/alz70856_104027

TRanslational Initiative to DE‐risk NeuroTherapeutics (TRIDENT) – A revolutionary pre‐clinical approach to maximize the predictive validity of pre‐clinical evaluation

2025· article· en· W7117259938 on OpenAlexaffabout
Sriram Jayabal, Ali R. Khan, Edward A. Fon, Jaqueline Sullivan, Joel C. Watts, Justine Cléry, Liisa A.M. Galea, Lisa M Saksida, Mallar Chakravarty, Marco AM Prado, E. Richard Gold, Thomas M. Durcan, Timothy J. Bussey, Vânia F. Prado, Ravi S. Menon

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicPluripotent Stem Cells Research
Canadian institutionsUniversity of TorontoMcGill UniversityMontreal Neurological Institute and HospitalCentre for Addiction and Mental HealthWestern University
Fundersnot available
KeywordsProcess (computing)Predictive validityProcess validationPharmaceutical industry

Abstract

fetched live from OpenAlex

BACKGROUND: Neurodegenerative diseases such as Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Multiple System Atrophy (MSA), are complex and poorly understood conditions characterized by progressive neuronal degeneration, affecting brain structure, function, and behavior. Cognitive impairment is seen in all these disorders despite heterogeneous clinical presentation, even in primarily motor diseases such as PD, causing hardship for the individuals and their caregivers. Dementia alone presents a growing public health crisis globally. Canada's annual dementia-related healthcare costs are projected to rise from $19.7 billion in 2011 to $92.8 billion by 2031. Additionally, the lack of effective treatments and the high failure rate (92%) of clinical trials for new central nervous system (CNS) therapies underscores the immediate need for effective pre-clinical approaches that can reliably predict success in clinical trials. High failure stems from four key issues: neglect of human-relevant cognitive measures, lack of sex and age factors, reliance on single-investigator studies, and poor reproducibility due to limited collaboration and sociocultural barriers. METHOD: The TRanslational Initiative to DE-risk NeuroTherapeutics (TRIDENT), with its novel platform for pre-clinical evaluation, addresses these critical gaps. TRIDENT integrates three advanced model systems- newly developed human-induced pluripotent stem cells (iPSCs) and organoids, as well as new humanized mouse and marmoset models-into a unified platform to dramatically improve the predictive validity of the pre-clinical to clinical outcomes. TRIDENT leverages the human-relevant touchscreen-based cognitive tasks in mice and marmosets, which are highly translatable to humans. Further, TRIDENT incorporates Sex-Based Analysis (SBA)+ and open science principles across all stages of preclinical evaluation, fostering inclusivity, collaboration, reproducibility, and accessibility. With testing facilities at McGill University, the University of Toronto, and the Center for Addiction and Mental Health, TRIDENT ensures robust multi-site validation of results. Currently, TRIDENT is evaluating compounds for alpha-synucleinopathies and AD using these models to validate the platform. RESULT: TRIDENT offers a revolutionary solution for developing effective therapies by maximizing predictive validity and de-risking the drug discovery process. CONCLUSION: This will transform the current approaches of pre-clinical testing in neurodegenerative disorders, making the process attractive to pharmaceutical and biotechnology industries to find effective cures and therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.084
metaresearch head score (Gemma)0.059
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.084
Threshold uncertainty score0.445

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0840.059
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0010.003
Scholarly communication0.0040.003
Open science0.0020.006
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.104
GPT teacher head0.397
Teacher spread0.293 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicPluripotent Stem Cells Research→French-language works237,207→